B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.